CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pelthos Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pelthos Therapeutics Inc
685 Us Highway One
Phone: (917) 644-6313p:917 644-6313 NORTH BRUNSWICK, NJ  08902  United States Ticker: PTHSPTHS
Business Summary
Pelthos Therapeutics Inc., formerly Channel Therapeutics Corporation, is a biopharmaceutical company focused on commercializing therapeutic products for high unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. ZELSUVMI is an FDA-designated novel drug, and a prescription medication approved for the treatment of molluscum that can be administered at home by parents, patients, and caregivers. The Company is also evaluating the path forward for its existing NaV 1.7 development programs for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board PeterGreenleaf 7/1/2025 7/1/2025
President, Chief Executive Officer, Director ScottPlesha 7/1/2025 7/1/2025
Chief Financial Officer, Treasurer, Company Secretary Francis P.Knuettel 59 7/1/2025 6/10/2022
4 additional Officers and Directors records available in full report.

Business Names
Business Name
CHRO
PTHS

General Information
Number of Employees: 4 (As of 3/26/2025)
Outstanding Shares: 3,029,501 (As of 7/2/2025)
Shareholders: 16
Stock Exchange: ASE
Federal Tax Id: 863335449


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 12, 2025